Xtl Biopharmaceuticals (XTLB) Cash & Current Investments (2009 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Cash & Current Investments for 17 consecutive years, with $76000.0 the latest figure, recorded in Q4 2025.

• Quarterly Cash & Current Investments fell 93.35% year-over-year to $76000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $76000.0 (down 93.35% YoY) and the FY2025 annual result came in at $76000.0, down 93.35% from the prior year.
• Cash & Current Investments slipped to $76000.0 in Q4 2025 per XTLB's latest filing, from $259000.0 in the prior quarter.
• Over the last five years, Cash & Current Investments for XTLB reached as high as $6.3 million in Q2 2021 and fell as low as $76000.0 in Q4 2025.
• A 5-year average of $2.7 million and a median of $2.4 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2021 — Cash & Current Investments jumped 65.23% — and 2025, when it sank 93.35%.
• Year by year, Cash & Current Investments stood at $6.1 million in 2021, then tumbled by 39.27% to $3.7 million in 2022, then plunged by 46.09% to $2.0 million in 2023, then sank by 43.02% to $1.1 million in 2024, then plunged by 93.35% to $76000.0 in 2025.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $76000.0, $259000.0, and $1.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.